News & Views
IXICO to run New Trial in Huntington’s Disease
May 14 2015
IXICO plc, a company specialising in brain health has been awarded a contract for a third clinical trial in Huntington’s disease (‘HD’) by a new US-based drug development specialty pharmaceutical customer. The contract is for an early phase trial for a novel treatment where IXICO will be providing a battery of advanced MRI imaging techniques and clinical trial endpoints.
This follows the announcements in May and November 2014 of contracts awarded and then extended with two top 15 pharmaceutical companies. This third contract extends and consolidates IXICO’s presence in, and revenues to be derived from, this important disease area and further expands the Company’s track record and capabilities in advanced MRI imaging techniques.
Professor Derek Hill, Chief Executive of IXICO, commented: “This third contract in Huntington’s disease is gratifying recognition of the success of our developing specialisation in both this disease area and in advanced MRI imaging techniques. These growth areas complement our well established position in the provision of similar support for clinical trials in Alzheimer’s disease.”
Digital Edition
Lab Asia 31.6 Dec 2024
December 2024
Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...
View all digital editions
Events
Jan 22 2025 Tokyo, Japan
Jan 22 2025 Birmingham, UK
Jan 25 2025 San Diego, CA, USA
Jan 27 2025 Dubai, UAE
Jan 29 2025 Tokyo, Japan